Czech National Bank Increases Holdings in Stryker Co. (NYSE:SYK)

Czech National Bank boosted its stake in Stryker Co. (NYSE:SYK - Free Report) by 6.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,878 shares of the medical technology company's stock after acquiring an additional 4,448 shares during the quarter. Czech National Bank's holdings in Stryker were worth $29,362,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker during the 4th quarter valued at $25,000. Capital A Wealth Management LLC bought a new position in Stryker during the 4th quarter worth approximately $26,000. Rakuten Securities Inc. grew its position in shares of Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker in the 4th quarter valued at approximately $30,000. Finally, BankPlus Trust Department acquired a new stake in shares of Stryker during the 4th quarter valued at approximately $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. BTIG Research set a $403.00 price target on shares of Stryker and gave the stock a "buy" rating in a research report on Monday, April 14th. Evercore ISI lowered their price target on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Citigroup reissued a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Truist Financial raised their price target on shares of Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of NYSE SYK traded up $1.11 during mid-day trading on Thursday, reaching $383.66. The company had a trading volume of 335,148 shares, compared to its average volume of 1,329,602. The firm has a market cap of $146.44 billion, a price-to-earnings ratio of 49.44, a PEG ratio of 2.93 and a beta of 0.93. The business's 50-day simple moving average is $369.68 and its 200 day simple moving average is $376.11. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The company's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.50 EPS. On average, research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.